fbpx
The Max Foundation Welcomes Bryan Murphy-Eustis as Vice President of Programs

The Max Foundation Welcomes Bryan Murphy-Eustis as Vice President of Programs

We are delighted to announce that Bryan Murphy-Eustis, MBA, MPH, is joining The Max Foundation’s Executive Team as Vice President of Programs.

Bryan joins the team with more than 18 years of experience building and leading high-impact mission-driven teams, most recently as Commercialization Lead for Medical Technologies at Global Good at Intellectual Ventures. Previously he served as Executive Director of PIH Liberia and Chief Operating Officer of Ebola Responses at Partners in Health, where he led clinical and operational teams that rapidly initiated and scaled services to 20 treatment facilities across two countries.

“It’s an incredible privilege to be joining The Max Foundation,” says Bryan. “That so many people are still prohibited from accessing live-saving medication is a grave injustice. I’ve long been familiar with The Max Foundation’s amazing work and I am honored to support such a vital effort toward increasing access to care.”

The Max Foundation CEO, Pat Garcia-Gonzalez, notes: “We added the VP of Programs position at our organization to reflect our growing commitment to patients and the long-term sustainability of our programs. As someone deeply committed to mission and impact and with a strong background in operations, Bryan fits right in. I look forward to working closely with Bryan to develop our potential towards a vision where all people can face cancer with dignity and hope.”

We’re excited about Bryan’s invaluable experience to help us shape a new decade of growth and impact for bridging access to treatment and care for people facing cancer worldwide.

Please join us in welcoming Bryan to The Max Foundation team!

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

    The Max Foundation, BeiGene, and the BeiGene Foundation Announce Collaboration to Advance Health Equity by Providing Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

    SEATTLE, Washington – May 17, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the….

  • Innovator Jerry Radich of Fred Hutch joins The Max Foundation’s Executive Board

    Innovator Jerry Radich of Fred Hutch joins The Max Foundation’s Executive Board

    The Max Foundation is thrilled to welcome longtime advisor, Dr. Jerald Radich of the Fred Hutchinson Cancer Research Institute into the Executive Board.  Dr. Radich has been a guiding star in our innovative work for many years helping people face cancer with dignity and hope, especially in the area of improving access to critical diagnostics in low- and middle-income countries.

  • First Doses of CLL treatment provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

    First Doses of CLL treatment provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation

    Armenia and Nepal are the first of 29 countries to receive CLL treatment SEATTLE & BASEL & BEIJING & CAMBRIDGE, Mass. – March 13, 2024 — The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and….

Provide access to treatment every month, year-round

Chronic cancers require monthly treatment and frequent diagnostic tests, sometimes indefinitely. That’s why monthly giving is so impactful at The Max Foundation.

For just $10/month, you can help ensure people receive uninterrupted care and support for as long as they need. Join the Champions Circle of global givers today and receive an exclusive welcome gift upon sign up!

Give Monthly

This will close in 0 seconds